Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib and Gemcitabine in Metastatic Refractory Renal Cell Carcinoma
NCT01834183Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2013
- Primary completion
- Jun 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of tivozanib in renal cell carcinoma (RCC), sponsored by Dana-Farber Cancer Institute. Planned start Jun 2013; status: withdrawn.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01834183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834183.